Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Teck Resources (TECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Teck Resources — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Teck Resources trades at $64.44 (market cap $32.79B). The key difference: Teck Resources is far larger — about 11.5× Dyne Therapeutics Inc. Common Stock's market cap, and Teck Resources pays a 0.53% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Teck Resources for 15 Days on average.
| DYN | TECK | |
|---|---|---|
Market Cap | $2.86B | $32.79B |
Volume | 3,341,579 | 1,600,168 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $71.97 |
52-Week Low | $14.60 | $38.23 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $2.18B | $35.41B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TECK trades at $67.17, down 0.55% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue and net income are projected to grow significantly in 2026, supported by a 17.85% net margin. Analyst consensus is strongly bullish, with 69% buy ratings, amid positive news flow including inclusion in Forbes' top companies for women and copper price optimism.
Outlook remains positive given earnings momentum and copper demand tailwinds, but risks include commodity price volatility and execution of the Anglo American merger. Cash flow turned positive in 2026 forecasts, though 2025 saw a net outflow. The stock offers value with a P/E of 18.82 and EV/EBITDA of 7.77, but investors should monitor merger progress and global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Teck Resources
Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.
Read more on TECK →
